POINT Biopharma Global Inc (PNT) Stock
PNT is no longer traded. POINT Biopharma Global was acquired by Eli Lilly (LLY) on January 8, 2024.
Each PNT share was exchanged for $12.50 in cash. Prices on this page are historical; the last trade was December 26, 2023 at $12.50.
See Eli Lilly (LLY) stock →POINT Biopharma Global stock price history
PNT final trading statistics
- Final close
- $12.50
- Final trading day
- Dec 26, 2023
- Market cap at delisting
- $1.33B
- Shares outstanding
- 106.57M
- Final 52-week range
- $6.57 – $14.35
- Avg. volume (final 3 mo.)
- 3,833,597
- All-time high (split-adj.)
- $16.86 · Feb 2021
- All-time low (split-adj.)
- $4.83 · Dec 2021
- Return since IPO
- +4.0%
- Beta
- -0.00
- Book value / share
- $4.01
- Price / book
- 3.12
POINT Biopharma Global annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $226.58M | $98.3M | $0.82 |
| FY2021 | $0.00 | -$45.9M | -$0.58 |
| FY2020 | $0.00 | -$13.4M | -$0.03 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About POINT Biopharma Global Inc
POINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-alpha inhibitor targeting program being developed for use in various tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana. As of December 27, 2023, POINT Biopharma Global Inc. operates as a subsidiary of Eli Lilly and Company.
POINT Biopharma Global stock FAQ
What happened to POINT Biopharma Global stock?
POINT Biopharma Global was acquired by Eli Lilly (LLY) on January 8, 2024. Shareholders received $12.50 in cash for each share. PNT stock stopped trading on the Nasdaq, with a final close of $12.50 on December 26, 2023.
What did POINT Biopharma Global shareholders receive?
Each PNT share was converted into $12.50 in cash. The deal was valued at about $1.4 billion.
Is PNT stock still trading?
No. PNT was delisted from the Nasdaq on January 8, 2024 and no longer trades on a U.S. exchange.
What was the last price of PNT stock?
PNT closed at $12.50 on its final trading day, December 26, 2023, for a market value of about $1.33B.
What were POINT Biopharma Global's revenue and earnings in its last full fiscal year?
POINT Biopharma Global reported revenue of $226.58M and net income of $98.3M in fiscal 2022, its last full year as a public company.
When did POINT Biopharma Global go public?
POINT Biopharma Global Inc stock began trading on July 8, 2020.